Janux Therapeutics Inc.

Company Overview

Business Model: Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company leverages its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platform technologies. These platforms are designed to create therapeutics that direct the immune system to eradicate tumors or deplete target cells while minimizing systemic toxicity, cytokine release syndrome (CRS), and healthy tissue toxicity, and improving pharmacokinetics for extended half-life.

Market Position: Janux Therapeutics, Inc. operates in the highly competitive immuno-oncology and autoimmune disease markets. Its TRACTr and TRACIr platforms aim to overcome limitations of prior T cell engager (TCE) technologies, such as on-target healthy tissue immune activation, CRS, and poor pharmacokinetics, by engineering tumor-specific activation and extended serum half-life. The ARM platform is designed to enable rapid, deep, and durable B-cell depletion with a large safety window and reduced CRS for autoimmune diseases. The company's lead candidates target clinically validated antigens like PSMA and EGFR in oncology, and CD19 in autoimmune diseases.

Recent Strategic Developments:

• JANX007 (PSMA TRACTr): Updated interim Phase 1a clinical data in December 2025 demonstrated durability across once-weekly (QW) and every-two-week (Q2W) cohorts, a manageable safety profile with primarily Grade 1 and 2 CRS, and rapid, deep PSA reductions in preliminary Phase 1b taxane-naïve patients. Phase 1b expansion studies were initiated in May 2025 to evaluate JANX007 in taxane-naïve mCRPC, in combination with darolutamide, and in patients whose disease progressed after PARP inhibitor therapy.
• JANX008 (EGFR TRACTr): Phase 1a expansion cohorts were initiated in December 2025 in selected solid tumor indications, building on early clinical data from February 2024 that showed anti-tumor activity across multiple tumor types with low-grade CRS and predominantly low-grade treatment-related adverse events.
• JANX011 (CD19-ARM): A Phase 1 clinical study was initiated to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers for autoimmune diseases.
• Merck Sharp & Dohme Corp. Collaboration: In August 2025, the first patient was dosed in the lead collaboration program with Merck Sharp & Dohme Corp. for TRACTr product candidates distinct from Janux Therapeutics, Inc.'s internal pipeline. Janux Therapeutics, Inc. is eligible for up to $500.5 million per target in upfront and milestone payments, plus royalties.
• Bristol Myers Squibb Collaboration: In January 2026, Janux Therapeutics, Inc. entered into an exclusive license and collaboration agreement with Bristol Myers Squibb for an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen. Janux Therapeutics, Inc. received an upfront payment of $15.0 million and is eligible for up to $785.0 million in milestone payments (including a $35.0 million near-term milestone) and tiered royalties on global net sales.

Geographic Footprint: Janux Therapeutics, Inc.'s corporate headquarters and primary operations are located in San Diego, California, United States. All of the company's assets are held in the United States. While its collaborations are with global pharmaceutical companies (Merck Sharp & Dohme Corp. and Bristol Myers Squibb), and it contracts with international vendors (e.g., WuXi Biologics (Hong Kong) Limited in China), its direct operational footprint is concentrated in the U.S.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A (Revenue is collaboration-based, not product sales)
• Operating Margin: -1577.0% (Calculated as Loss from Operations / Total Revenue)
• Net Margin: -1136.0% (Calculated as Net Loss / Total Revenue)

Investment in Growth:

• R&D Expenditure: $125.9 million (1259.0% of revenue)
• Capital Expenditures: $1.0 million
• Strategic Investments:
  • Received $10.0 million in development milestone payments from Merck Sharp & Dohme Corp. in August 2025.
  • Received $15.0 million upfront payment from Bristol Myers Squibb in January 2026 (subsequent event).

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported.
• Dividend Payments: None declared or paid.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: No specific future capital return commitments disclosed, as the company intends to retain future earnings for business development and expansion.

Balance Sheet Position:

• Cash and Equivalents: $52.3 million
• Total Debt: No long-term debt reported.
• Net Cash Position: $967.4 million (Cash, cash equivalents, restricted cash, and short-term investments)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no long-term debt is reported. Operating lease liabilities have future minimum payments of $28.965 million through 2030 and thereafter.

Cash Flow Generation:

• Operating Cash Flow: $(82.2) million
• Free Cash Flow: $(83.2) million (Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly provided.

Operational Excellence

Production & Service Model: Janux Therapeutics, Inc. does not own or operate cGMP manufacturing facilities. It relies on third-party manufacturers and suppliers for raw materials and starting components for its TRACTr, TRACIr, and ARM product candidates. The manufacturing processes for these molecules are designed to resemble those for monoclonal antibodies, allowing for high recombinant expression in Chinese hamster ovary cells and purification using standard techniques like Protein A affinity chromatography. The company believes these attributes contribute to a relatively lower cost-per-dose compared to monoclonal antibodies.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing Partners: Third-party contract manufacturers for Bulk Drug Substance (BDS) and drug product. Currently, BDS for each product candidate is covered by single-source suppliers.
• Cell Line License: WuXi Biologics (Hong Kong) Limited - provides a non-exclusive, worldwide, sublicensable license for a cell line used to manufacture components of PSMA-TRACTr and EGFR-TRACTr product candidates.
• Raw Materials: Relies on third-party suppliers for raw materials and starting components, some of which are located outside the United States.

Facility Network:

• Corporate Headquarters & Research Facility: San Diego, California, United States. Leases office and laboratory space under a lease agreement commenced July 2022, expiring January 2033. Also has a sublease for additional office space expiring January 2028.
• Manufacturing: Relies on third-party cGMP manufacturing facilities.
• Research & Development: Conducted at its San Diego facility and through third-party contract research organizations (CROs).

Operational Metrics: Not explicitly disclosed beyond general statements about manufacturability and stability assessments.

Market Access & Customer Relationships

Go-to-Market Strategy: Janux Therapeutics, Inc. currently has no internal sales, marketing, or distribution capabilities or experience. For any approved products, it plans to either develop its own sales and marketing organization or outsource these functions to third parties.

Customer Portfolio:

• Strategic Partnerships:
  • Merck Sharp & Dohme Corp. - collaboration for TRACTr product candidates for cancer treatment.
  • Bristol Myers Squibb - collaboration for a novel tumor-activated therapeutic targeting a solid tumor antigen.
• Customer Concentration: All revenue recognized to date has been derived from the collaboration agreement with Merck Sharp & Dohme Corp.

Geographic Revenue Distribution: All revenue recognized to date has been derived from the collaboration agreement with Merck Sharp & Dohme Corp., which is a U.S.-based entity. The company's product candidates, if approved, are intended for global markets.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The immuno-oncology and autoimmune disease segments are particularly dynamic, with new technologies and therapies constantly emerging. The market for TCEs in solid tumors faces challenges related to systemic toxicity (CRS) and on-target healthy tissue toxicity, which Janux Therapeutics, Inc. aims to address with its novel platforms.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Immuno-oncology and Autoimmune Treatments: AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead, GSK, Johnson & Johnson, Merck & Co., Lilly, Novartis, Pfizer, Regeneron, Sanofi, Takeda, Roche/Genentech.
• PSMA-targeting therapeutics: AbbVie, Amgen, Crescendo Biologics, GSK, Johnson & Johnson, Lava Therapeutics, Chugai/Roche, Regeneron, Takeda, Vir Biotechnology, Xilio Therapeutics (TCEs); Astellas, Regeneron, Johnson & Dohme Corp., Roche, Xencor (immunomodulators); AbbVie, AstraZeneca, Daichii/Merck, Novartis, Johnson & Johnson (antibody-drug conjugates); Gilead (CAR T cell therapies); AstraZeneca, Bristol Myers Squibb, Johnson & Johnson, Novartis, Lantheus/Lilly, Telix, Bayer (radiopharmaceuticals).
• EGFR-targeting therapeutics: Genmab/Janssen’s amivantamab, Roche’s bevacizumab, Amgen’s panitumumab, Eli Lilly/Merck KGaA’s cetuximab, Bayer’s regorafenib, Eli Lilly’s ramucirumab (approved); AstraZeneca, Bristol Myers Squibb, Dragonfly, KangaBio, Lava Therapeutics/Pfizer, Merus, Regeneron, Chugai/Roche, Vir Biotechnology (clinical-stage).
• CD28-based multispecifics: Regeneron’s nezastomig, REGN5668, REGN7075; Sanofi’s SAR443216; Janssen/Xencor’s XmAb808; Johnson & Johnson’s JNJ-9401.
• Protease-activated therapeutics: Adagene, Astellas, BioAtla, Chugai Pharmaceutical Co./Roche Holding AG, CytomX Therapeutics, Merck & Co., Regeneron, Vir Biotechnology, Xilio Therapeutics.
• CD19-targeting autoimmune therapies: AbbVie/Genmab, Amgen, Antengene, Bristol Myers Squibb, Cabaletta, Candid Therapeutics, Cullinan Therapeutics, Fate Therapeutics, Gilead, Kyverna Therapeutics, Lilly, Novartis, Regeneron, Roche/Genentech, TG Therapeutics, Xencor, Zenas BioPharma (B-cell depletion); Argenx, Biogen, Dianthus Therapeutics, Immunovant, Johnson & Johnson, Sanofi, UCB (autoantibody/humoral immunity modulators); GSK, Novartis, Otsuka, RemeGen, Vera Therapeutics, Vor Biopharma, Vertex (B-cell survival/aplasia pathways).

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in immuno-oncology and autoimmune disease, including advanced cell therapies and novel small molecules.

Competitive Response Strategy: Janux Therapeutics, Inc. aims to maintain its competitive advantage by leveraging its proprietary TRACTr, TRACIr, and ARM platforms to develop differentiated product candidates that address the safety and pharmacokinetic limitations of prior generations of immunotherapies. The company also pursues strategic partnerships to maximize the global potential of its platforms.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The market opportunity for Janux Therapeutics, Inc.'s product candidates may be limited to patients ineligible for or who have failed prior treatments, and estimates of target patient populations may be inaccurate. The rapidly evolving immuno-oncology and autoimmune industries mean competitors may introduce superior or more cost-effective products.
• Technology Disruption: As a company focused on novel technologies, there is a risk that new technologies could render its platforms obsolete or less attractive. Adverse developments in similar approaches by other companies could negatively impact the perceived value of Janux Therapeutics, Inc.'s programs.
• Customer Concentration: All revenue to date has been from a single customer (Merck Sharp & Dohme Corp.), creating dependency risk.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Janux Therapeutics, Inc. relies on third-party manufacturers, including single-source suppliers for Bulk Drug Substance (BDS), increasing the risk of supply limitations or interruptions. Manufacturing complex biologics involves inherent risks of lot failures, recalls, or expiry due to process deviations.
• Geographic Concentration: Reliance on international suppliers, such as WuXi Biologics (Hong Kong) Limited in China, exposes the company to risks from international trade policies, tariffs, sanctions, and geopolitical tensions, which could disrupt supply or increase costs.
• Capacity Constraints: Difficulties in scaling up manufacturing for clinical trials or commercialization could impair development and commercialization efforts.
• Key Personnel Dependence: The company is highly dependent on its key managerial, scientific, and medical personnel. Competition for skilled talent is intense, and the loss of key individuals could delay product development.
• Growth Management: Expected expansion in development, regulatory, and operational capabilities may present difficulties in managing growth, potentially disrupting operations.
• Reliance on Third Parties: Dependence on CROs and other third parties for preclinical and clinical studies means Janux Therapeutics, Inc. has less control over timelines and quality, and non-compliance could lead to delays or increased costs.

Financial & Regulatory Risks

• Market & Financial Risks: Janux Therapeutics, Inc. has a limited operating history, has incurred significant net losses ($113.6 million in 2025), and anticipates continued losses. It will require substantial additional capital to fund operations beyond the next 12 months, and failure to raise funds could force delays or termination of programs. Equity financing will dilute existing stockholders.
• Product Liability: The use of product candidates in clinical trials and potential commercial sales exposes the company to product liability claims, which could result in substantial costs, reputational harm, or regulatory actions.
• Regulatory & Compliance Risks: The regulatory approval process is lengthy, expensive, and uncertain. Product candidates may not achieve favorable clinical trial results or receive marketing approval. Even if approved, products will be subject to extensive ongoing regulatory oversight, including post-marketing requirements, and potential restrictions or withdrawal if safety issues arise or compliance fails. Changes in regulatory policies or government agency disruptions could cause delays.
• Healthcare Laws and Regulations: Operations are subject to U.S. federal and state, EU, and foreign healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, Physician Payments Sunshine Act), and data privacy/security laws (e.g., HIPAA, CCPA, GDPR). Non-compliance could lead to substantial penalties, litigation, and reputational harm.
• Pricing and Reimbursement: Unfavorable pricing regulations or third-party coverage and reimbursement policies could limit commercial success. Government cost containment programs (e.g., Medicare Drug Price Negotiation Program, EU HTA Regulation, Pharma Package) could reduce drug prices and profitability.

Geopolitical & External Risks

• Geopolitical Exposure: International trade policies, tariffs, sanctions, and trade barriers (e.g., U.S. actions against Chinese biotechnology companies, Russia-Ukraine conflict, Middle East war) may adversely affect business, particularly supply chain and international collaborations.
• Health Epidemics/Pandemics: Could cause significant disruptions to clinical trials, supply chain, and business development activities, impacting timelines and financial stability.
• Unstable Market and Economic Conditions: Global economic volatility, including inflation, bank failures, and recessions, could impact access to capital, increase costs, and affect the survival of service providers.
• Cybersecurity Threats: Dependence on information technology systems and third-party services exposes the company to cyber-attacks and security incidents, risking data loss, operational disruption, regulatory investigations, and reputational harm.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• TRACTr Platform: Develops T cell engagers (TCEs) with tumor antigen-binding and CD3 T cell binding domains. Designed to overcome liabilities of prior TCEs (CRS, on-target toxicity, short half-life) through tumor-specific activation and extended serum half-life.
• TRACIr Platform: Produces bispecifics with tumor antigen-binding and costimulatory CD28 binding domains, designed to enhance T cell activation and durability.
• ARM Platform: Redesigns bispecific TCEs for controlled T cell activation and expansion followed by contraction, aiming for deep and durable target cell depletion with improved safety and convenience in autoimmune diseases and oncology.
• Innovation Pipeline: Actively pursuing additional TRACTr, TRACIr, and ARM programs against various clinically validated targets. Demonstrated ability to develop masked tumor-binding domains in less than six months.

Intellectual Property Portfolio:

• Patent Strategy: As of February 10, 2026, Janux Therapeutics, Inc. owns 4 U.S. patents, 42 pending U.S. provisional and non-provisional patent applications, 9 pending Patent Cooperation Treaty (PCT) applications, 7 foreign patents, and 115 foreign patent applications.
• Patent Holdings:
  • General TRACTr/TRACIr platforms: 1 U.S. non-provisional patent application, 6 foreign patent applications.
  • Components/aspects of TRACTr/TRACIr platforms: 1 U.S. patent, 2 U.S. non-provisional patent applications, 19 foreign patent applications, 6 foreign patents.
  • TRACTr platform components: 3 U.S. non-provisional patent applications, 15 foreign patent applications.
  • JANX007 specific: 1 U.S. patent, 8 U.S. provisional/non-provisional patent applications, 26 foreign patent applications, 1 foreign patent.
  • JANX008 specific: 4 U.S. non-provisional patent applications, 2 U.S. patents, 1 PCT patent application, 18 foreign patent applications.
  • PSMA x CD28 TRACIr specific: 2 PCT patent applications, 2 foreign patent applications.
  • Unnamed TRACTr/TRACIr programs: 11 U.S. provisional/non-provisional patent applications, 3 PCT patent applications, 27 foreign patent applications.
  • TRACIr platform components: 1 PCT patent application, 2 foreign patent applications.
  • Other proprietary antibodies/compounds: 13 U.S. provisional/non-provisional patent applications, 2 PCT patent applications.
• Expiration: Patents and patents issuing from pending applications are expected to expire between 2038 and 2046, absent any patent term adjustments or extensions.
• Licensing Programs: Co-owns 1 U.S. non-provisional patent application, 1 PCT patent application, and 5 foreign patent applications with Merck Sharp & Dohme LLC, expected to expire in 2045.
• Trade Secrets: Relies on trade secrets and know-how for unpatentable aspects, processes, and other proprietary information.

Technology Partnerships:

• Strategic Alliances:
  • Merck Sharp & Dohme Corp.: Research collaboration and exclusive license agreement for TRACTr product candidates.
  • Bristol Myers Squibb: Exclusive license and collaboration agreement for a novel tumor-activated therapeutic.
• Research Collaborations: Not explicitly detailed beyond the Merck Sharp & Dohme Corp. and Bristol Myers Squibb agreements.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company emphasizes its ability to attract and retain highly qualified managerial, scientific, and medical personnel. It offers competitive compensation and equity incentive plans to retain valuable employees.

Board Composition: The Board of Directors is classified with three-year staggered terms. The audit committee of the board of directors is responsible for overseeing cybersecurity risk management processes.

Human Capital Strategy

Workforce Composition:

• Total Employees: 109 full-time employees as of December 31, 2025.
• Geographic Distribution: 102 employees based at headquarters in San Diego, California.
• Skill Mix: 84 employees engaged in research and development; 25 engaged in general and administrative activities.

Talent Management:

• Acquisition & Retention: The company aims to identify, recruit, retain, incentivize, and integrate employees. It monitors recruiting efforts and tracks turnover rates for business-critical talent.
• Employee Value Proposition: Offers competitive pay, cash incentives, and equity incentive plans (stock options, restricted stock units, employee stock purchase plan) that vest over time. Standard employee benefits include paid/unpaid leaves, medical/dental/vision insurance, 401(k) plan, disability, life insurance, health savings/flexible spending accounts, and wellness programs.

Diversity & Development: Not explicitly detailed beyond general talent management and employee value proposition.

Environmental & Social Impact

Environmental Commitments: Janux Therapeutics, Inc. and its third-party contractors are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation, and disposal of hazardous materials and wastes. The company contracts with third parties for waste disposal.

Supply Chain Sustainability: No specific supply chain sustainability initiatives or programs are disclosed in the filing.

Social Impact Initiatives: No specific social impact or community investment initiatives are disclosed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• United States: Subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA), governing research, development, testing, manufacturing, approval (BLA), labeling, promotion, and distribution of biological products. Expedited programs like Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval are available. Orphan Drug Designation provides market exclusivity. Post-approval requirements include cGMP, GCP, adverse event reporting, and potential Risk Evaluation and Mitigation Strategies (REMS).
• European Union: Subject to regulation by the European Medicines Agency (EMA) and European Commission. Clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014 (CTR), effective January 31, 2025. Marketing authorization is primarily through the centralized procedure. Conditional approval and accelerated assessment procedures are available. Orphan Medicinal Product Designation provides 10 years of market exclusivity. Post-authorization requirements include pharmacovigilance systems and Risk Management Plans (RMPs). The Health Technology Assessment (HTA) Regulation (effective January 12, 2025) aims to boost cooperation among EU Member States in assessing health technologies. The Pharma Package (political agreement December 11, 2025) proposes changes to market protection periods and the Bolar exemption.

Trade & Export Controls: The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. Geopolitical actions, tariffs, and trade barriers could adversely affect its business, particularly given its reliance on international suppliers.

Legal Proceedings: Janux Therapeutics, Inc. is not currently a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Not applicable due to net losses and a full valuation allowance against deferred tax assets.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, the company had $138.9 million in U.S. federal NOL carryforwards (of which $138.4 million have an indefinite carryforward period, limited to 80% of future taxable income) and $182.9 million in state NOL carryforwards (beginning to expire in 2037).
• Research & Development (R&D) Credit Carryforwards: As of December 31, 2025, the company had $14.6 million in federal R&D credit carryforwards (beginning to expire in 2037) and $7.4 million in state R&D credit carryforwards (do not expire).
• Valuation Allowance: Maintains a full valuation allowance against its deferred tax assets ($90.0 million as of December 31, 2025) due to uncertainties regarding their realization.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, which includes expensing of domestic R&E expenditures, increased interest expense deduction limits, and 100% bonus depreciation, did not have a material impact on the company's current or future effective tax rate or cash taxes paid for the year ended December 31, 2025.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains workers’ compensation insurance. Plans to expand product liability insurance coverage upon obtaining marketing approval for product candidates. Maintains cybersecurity insurance.
• Risk Transfer Mechanisms: Does not maintain insurance for environmental liability or toxic tort claims.
• Cybersecurity: Implements various information security processes and measures, including an incident response policy, vulnerability management, disaster recovery plan, encryption, network security controls, and employee training. Utilizes third-party service providers for cybersecurity assessments and support.### Company Overview Business Model: Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company leverages its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platform technologies. These platforms are designed to create therapeutics that direct the immune system to eradicate tumors or deplete target cells while minimizing systemic toxicity, cytokine release syndrome (CRS), and healthy tissue toxicity, and improving pharmacokinetics for extended half-life.

Market Position: Janux Therapeutics, Inc. operates in the highly competitive immuno-oncology and autoimmune disease markets. Its TRACTr and TRACIr platforms aim to overcome limitations of prior T cell engager (TCE) technologies, such as on-target healthy tissue immune activation, CRS, and poor pharmacokinetics, by engineering tumor-specific activation and extended serum half-life. The ARM platform is designed to enable rapid, deep, and durable B-cell depletion with a large safety window and reduced CRS for autoimmune diseases. The company's lead candidates target clinically validated antigens like PSMA and EGFR in oncology, and CD19 in autoimmune diseases.

Recent Strategic Developments:

• JANX007 (PSMA TRACTr): Updated interim Phase 1a clinical data in December 2025 demonstrated durability across once-weekly (QW) and every-two-week (Q2W) cohorts, a manageable safety profile with primarily Grade 1 and 2 CRS, and rapid, deep PSA reductions in preliminary Phase 1b taxane-naïve patients. Phase 1b expansion studies were initiated in May 2025 to evaluate JANX007 in taxane-naïve mCRPC, in combination with darolutamide, and in patients whose disease progressed after PARP inhibitor therapy.
• JANX008 (EGFR TRACTr): Phase 1a expansion cohorts were initiated in December 2025 in selected solid tumor indications, building on early clinical data from February 2024 that showed anti-tumor activity across multiple tumor types with low-grade CRS and predominantly low-grade treatment-related adverse events.
• JANX011 (CD19-ARM): A Phase 1 clinical study was initiated to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers for autoimmune diseases.
• Merck Sharp & Dohme Corp. Collaboration: In August 2025, the first patient was dosed in the lead collaboration program with Merck Sharp & Dohme Corp. for TRACTr product candidates distinct from Janux Therapeutics, Inc.'s internal pipeline. Janux Therapeutics, Inc. is eligible for up to $500.5 million per target in upfront and milestone payments, plus royalties.
• Bristol Myers Squibb Collaboration: In January 2026, Janux Therapeutics, Inc. entered into an exclusive license and collaboration agreement with Bristol Myers Squibb for an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen. Janux Therapeutics, Inc. received an upfront payment of $15.0 million and is eligible for up to $785.0 million in milestone payments (including a $35.0 million near-term milestone) and tiered royalties on global net sales.

Geographic Footprint: Janux Therapeutics, Inc.'s corporate headquarters and primary operations are located in San Diego, California, United States. All of the company's assets are held in the United States. While its collaborations are with global pharmaceutical companies (Merck Sharp & Dohme Corp. and Bristol Myers Squibb), and it contracts with international vendors (e.g., WuXi Biologics (Hong Kong) Limited in China), its direct operational footprint is concentrated in the U.S.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A (Revenue is collaboration-based, not product sales)
• Operating Margin: -1577.0% (Calculated as Loss from Operations / Total Revenue)
• Net Margin: -1136.0% (Calculated as Net Loss / Total Revenue)

Investment in Growth:

• R&D Expenditure: $125.9 million (1259.0% of revenue)
• Capital Expenditures: $1.0 million
• Strategic Investments:
  • Received $10.0 million in development milestone payments from Merck Sharp & Dohme Corp. in August 2025.
  • Received $15.0 million upfront payment from Bristol Myers Squibb in January 2026 (subsequent event).

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: None reported.
• Dividend Payments: None declared or paid.
• Dividend Yield: 0.0%
• Future Capital Return Commitments: No specific future capital return commitments disclosed, as the company intends to retain future earnings for business development and expansion.

Balance Sheet Position:

• Cash and Equivalents: $52.3 million
• Total Debt: No long-term debt reported.
• Net Cash Position: $967.4 million (Cash, cash equivalents, restricted cash, and short-term investments)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not applicable as no long-term debt is reported. Operating lease liabilities have future minimum payments of $28.965 million through 2030 and thereafter.

Cash Flow Generation:

• Operating Cash Flow: $(82.2) million
• Free Cash Flow: $(83.2) million (Operating Cash Flow - Capital Expenditures)
• Cash Conversion Metrics: Not explicitly provided.

Operational Excellence

Production & Service Model: Janux Therapeutics, Inc. does not own or operate cGMP manufacturing facilities. It relies on third-party manufacturers and suppliers for raw materials and starting components for its TRACTr, TRACIr, and ARM product candidates. The manufacturing processes for these molecules are designed to resemble those for monoclonal antibodies, allowing for high recombinant expression in Chinese hamster ovary cells and purification using standard techniques like Protein A affinity chromatography. The company believes these attributes contribute to a relatively lower cost-per-dose compared to monoclonal antibodies.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing Partners: Third-party contract manufacturers for Bulk Drug Substance (BDS) and drug product. Currently, BDS for each product candidate is covered by single-source suppliers.
• Cell Line License: WuXi Biologics (Hong Kong) Limited - provides a non-exclusive, worldwide, sublicensable license for a cell line used to manufacture components of PSMA-TRACTr and EGFR-TRACTr product candidates.
• Raw Materials: Relies on third-party suppliers for raw materials and starting components, some of which are located outside the United States.

Facility Network:

• Corporate Headquarters & Research Facility: San Diego, California, United States. Leases office and laboratory space under a lease agreement commenced July 2022, expiring January 2033. Also has a sublease for additional office space expiring January 2028.
• Manufacturing: Relies on third-party cGMP manufacturing facilities.
• Research & Development: Conducted at its San Diego facility and through third-party contract research organizations (CROs).

Operational Metrics: Not explicitly disclosed beyond general statements about manufacturability and stability assessments.

Market Access & Customer Relationships

Go-to-Market Strategy: Janux Therapeutics, Inc. currently has no internal sales, marketing, or distribution capabilities or experience. For any approved products, it plans to either develop its own sales and marketing organization or outsource these functions to third parties.

Customer Portfolio:

• Strategic Partnerships:
  • Merck Sharp & Dohme Corp.: Research collaboration and exclusive license agreement for TRACTr product candidates for cancer treatment.
  • Bristol Myers Squibb: Exclusive license and collaboration agreement for a novel tumor-activated therapeutic targeting a solid tumor antigen.
• Customer Concentration: All revenue recognized to date has been derived from the collaboration agreement with Merck Sharp & Dohme Corp.

Geographic Revenue Distribution: All revenue recognized to date has been derived from the collaboration agreement with Merck Sharp & Dohme Corp., which is a U.S.-based entity. The company's product candidates, if approved, are intended for global markets.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. The immuno-oncology and autoimmune disease segments are particularly dynamic, with new technologies and therapies constantly emerging. The market for TCEs in solid tumors faces challenges related to systemic toxicity (CRS) and on-target healthy tissue toxicity, which Janux Therapeutics, Inc. aims to address with its novel platforms.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Immuno-oncology and Autoimmune Treatments: AbbVie, Amgen, AstraZeneca, Biogen, Bristol Myers Squibb, Gilead, GSK, Johnson & Johnson, Merck & Co., Lilly, Novartis, Pfizer, Regeneron, Sanofi, Takeda, Roche/Genentech.
• PSMA-targeting therapeutics: AbbVie, Amgen, Crescendo Biologics, GSK, Johnson & Dohme Corp., Lava Therapeutics, Chugai/Roche, Regeneron, Takeda, Vir Biotechnology, Xilio Therapeutics (TCEs); Astellas, Regeneron, Johnson & Dohme Corp., Roche, Xencor (immunomodulators); AbbVie, AstraZeneca, Daichii/Merck, Novartis, Johnson & Dohme Corp. (antibody-drug conjugates); Gilead (CAR T cell therapies); AstraZeneca, Bristol Myers Squibb, Johnson & Dohme Corp., Novartis, Lantheus/Lilly, Telix, Bayer (radiopharmaceuticals).
• EGFR-targeting therapeutics: Genmab/Janssen’s amivantamab, Roche’s bevacizumab, Amgen’s panitumumab, Eli Lilly/Merck KGaA’s cetuximab, Bayer’s regorafenib, and Eli Lilly’s ramucirumab (approved); AstraZeneca, Bristol Myers Squibb, Dragonfly, KangaBio, Lava Therapeutics/Pfizer, Merus, Regeneron, Chugai/Roche, Vir Biotechnology (clinical-stage).
• CD28-based multispecifics: Regeneron’s nezastomig, REGN5668, REGN7075; Sanofi’s SAR443216; Janssen/Xencor’s XmAb808; Johnson & Dohme Corp.’s JNJ-9401.
• Protease-activated therapeutics: Adagene, Astellas, BioAtla, Chugai Pharmaceutical Co./Roche Holding AG, CytomX Therapeutics, Merck & Co., Regeneron, Vir Biotechnology, Xilio Therapeutics.
• CD19-targeting autoimmune therapies: AbbVie/Genmab, Amgen, Antengene, Bristol Myers Squibb, Cabaletta, Candid Therapeutics, Cullinan Therapeutics, Fate Therapeutics, Gilead, Kyverna Therapeutics, Lilly, Novartis, Regeneron, Roche/Genentech, TG Therapeutics, Xencor, Zenas BioPharma (B-cell depletion); Argenx, Biogen, Dianthus Therapeutics, Immunovant, Johnson & Dohme Corp., Sanofi, UCB (autoantibody/humoral immunity modulators); GSK, Novartis, Otsuka, RemeGen, Vera Therapeutics, Vor Biopharma, Vertex (B-cell survival/aplasia pathways).

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions in immuno-oncology and autoimmune disease, including advanced cell therapies and novel small molecules.

Competitive Response Strategy: Janux Therapeutics, Inc. aims to maintain its competitive advantage by leveraging its proprietary TRACTr, TRACIr, and ARM platforms to develop differentiated product candidates that address the safety and pharmacokinetic limitations of prior generations of immunotherapies. The company also pursues strategic partnerships to maximize the global potential of its platforms.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: The market opportunity for Janux Therapeutics, Inc.'s product candidates may be limited to patients ineligible for or who have failed prior treatments, and estimates of target patient populations may be inaccurate. The rapidly evolving immuno-oncology and autoimmune industries mean competitors may introduce superior or more cost-effective products.
• Technology Disruption: As a company focused on novel technologies, there is a risk that new technologies could render its platforms obsolete or less attractive. Adverse developments in similar approaches by other companies could negatively impact the perceived value of Janux Therapeutics, Inc.'s programs.
• Customer Concentration: All revenue to date has been from a single customer (Merck Sharp & Dohme Corp.), creating dependency risk.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Janux Therapeutics, Inc. relies on third-party manufacturers, including single-source suppliers for Bulk Drug Substance (BDS), increasing the risk of supply limitations or interruptions. Manufacturing complex biologics involves inherent risks of lot failures, recalls, or expiry due to process deviations.
• Geographic Concentration: Reliance on international suppliers, such as WuXi Biologics (Hong Kong) Limited in China, exposes the company to risks from international trade policies, tariffs, sanctions, and geopolitical tensions, which could disrupt supply or increase costs.
• Capacity Constraints: Difficulties in scaling up manufacturing for clinical trials or commercialization could impair development and commercialization efforts.
• Key Personnel Dependence: The company is highly dependent on its key managerial, scientific, and medical personnel. Competition for skilled talent is intense, and the loss of key individuals could delay product development.
• Growth Management: Expected expansion in development, regulatory, and operational capabilities may present difficulties in managing growth, potentially disrupting operations.
• Reliance on Third Parties: Dependence on CROs and other third parties for preclinical and clinical studies means Janux Therapeutics, Inc. has less control over timelines and quality, and non-compliance could lead to delays or increased costs.

Financial & Regulatory Risks

• Market & Financial Risks: Janux Therapeutics, Inc. has a limited operating history, has incurred significant net losses ($113.6 million in 2025), and anticipates continued losses. It will require substantial additional capital to fund operations beyond the next 12 months, and failure to raise funds could force delays or termination of programs. Equity financing will dilute existing stockholders.
• Product Liability: The use of product candidates in clinical trials and potential commercial sales exposes the company to product liability claims, which could result in substantial costs, reputational harm, or regulatory actions.
• Regulatory & Compliance Risks: The regulatory approval process is lengthy, expensive, and uncertain. Product candidates may not achieve favorable clinical trial results or receive marketing approval. Even if approved, products will be subject to extensive ongoing regulatory oversight, including post-marketing requirements, and potential restrictions or withdrawal if safety issues arise or compliance fails. Changes in regulatory policies or government agency disruptions could cause delays.
• Healthcare Laws and Regulations: Operations are subject to U.S. federal and state, EU, and foreign healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, Physician Payments Sunshine Act), and data privacy/security laws (e.g., HIPAA, CCPA, GDPR). Non-compliance could lead to substantial penalties, litigation, and reputational harm.
• Pricing and Reimbursement: Unfavorable pricing regulations or third-party coverage and reimbursement policies could limit commercial success. Government cost containment programs (e.g., Medicare Drug Price Negotiation Program, EU HTA Regulation, Pharma Package) could reduce drug prices and profitability.

Geopolitical & External Risks

• Geopolitical Exposure: International trade policies, tariffs, sanctions, and trade barriers (e.g., U.S. actions against Chinese biotechnology companies, Russia-Ukraine conflict, Middle East war) may adversely affect business, particularly supply chain and international collaborations.
• Health Epidemics/Pandemics: Could cause significant disruptions to clinical trials, supply chain, and business development activities, impacting timelines and financial stability.
• Unstable Market and Economic Conditions: Global economic volatility, including inflation, bank failures, and recessions, could impact access to capital, increase costs, and affect the survival of service providers.
• Cybersecurity Threats: Dependence on information technology systems and third-party services exposes the company to cyber-attacks and security incidents, risking data loss, operational disruption, regulatory investigations, and reputational harm.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• TRACTr Platform: Develops T cell engagers (TCEs) with tumor antigen-binding and CD3 T cell binding domains. Designed to overcome liabilities of prior TCEs (CRS, on-target toxicity, short half-life) through tumor-specific activation and extended serum half-life.
• TRACIr Platform: Produces bispecifics with tumor antigen-binding and costimulatory CD28 binding domains, designed to enhance T cell activation and durability.
• ARM Platform: Redesigns bispecific TCEs for controlled T cell activation and expansion followed by contraction, aiming for deep and durable target cell depletion with improved safety and convenience in autoimmune diseases and oncology.
• Innovation Pipeline: Actively pursuing additional TRACTr, TRACIr, and ARM programs against various clinically validated targets. Demonstrated ability to develop masked tumor-binding domains in less than six months.

Intellectual Property Portfolio:

• Patent Strategy: As of February 10, 2026, Janux Therapeutics, Inc. owns 4 U.S. patents, 42 pending U.S. provisional and non-provisional patent applications, 9 pending Patent Cooperation Treaty (PCT) applications, 7 foreign patents, and 115 foreign patent applications.
• Patent Holdings:
  • General TRACTr/TRACIr platforms: 1 U.S. non-provisional patent application, 6 foreign patent applications.
  • Components/aspects of TRACTr/TRACIr platforms: 1 U.S. patent, 2 U.S. non-provisional patent applications, 19 foreign patent applications, 6 foreign patents.
  • TRACTr platform components: 3 U.S. non-provisional patent applications, 15 foreign patent applications.
  • JANX007 specific: 1 U.S. patent, 8 U.S. provisional/non-provisional patent applications, 26 foreign patent applications, 1 foreign patent.
  • JANX008 specific: 4 U.S. non-provisional patent applications, 2 U.S. patents, 1 PCT patent application, 18 foreign patent applications.
  • PSMA x CD28 TRACIr specific: 2 PCT patent applications, 2 foreign patent applications.
  • Unnamed TRACTr/TRACIr programs: 11 U.S. provisional/non-provisional patent applications, 3 PCT patent applications, 27 foreign patent applications.
  • TRACIr platform components: 1 PCT patent application, 2 foreign patent applications.
  • Other proprietary antibodies/compounds: 13 U.S. provisional/non-provisional patent applications, 2 PCT patent applications.
• Expiration: Patents and patents issuing from pending applications are expected to expire between 2038 and 2046, absent any patent term adjustments or extensions.
• Licensing Programs: Co-owns 1 U.S. non-provisional patent application, 1 PCT patent application, and 5 foreign patent applications with Merck Sharp & Dohme LLC, expected to expire in 2045.
• Trade Secrets: Relies on trade secrets and know-how for unpatentable aspects, processes, and other proprietary information.

Technology Partnerships:

• Strategic Alliances:
  • Merck Sharp & Dohme Corp.: Research collaboration and exclusive license agreement for TRACTr product candidates.
  • Bristol Myers Squibb: Exclusive license and collaboration agreement for a novel tumor-activated therapeutic.
• Research Collaborations: Not explicitly detailed beyond the Merck Sharp & Dohme Corp. and Bristol Myers Squibb agreements.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company emphasizes its ability to attract and retain highly qualified managerial, scientific, and medical personnel. It offers competitive compensation and equity incentive plans to retain valuable employees.

Board Composition: The Board of Directors is classified with three-year staggered terms. The audit committee of the board of directors is responsible for overseeing cybersecurity risk management processes.

Human Capital Strategy

Workforce Composition:

• Total Employees: 109 full-time employees as of December 31, 2025.
• Geographic Distribution: 102 employees based at headquarters in San Diego, California.
• Skill Mix: 84 employees engaged in research and development; 25 engaged in general and administrative activities.

Talent Management:

• Acquisition & Retention: The company aims to identify, recruit, retain, incentivize, and integrate employees. It monitors recruiting efforts and tracks turnover rates for business-critical talent.
• Employee Value Proposition: Offers competitive pay, cash incentives, and equity incentive plans (stock options, restricted stock units, employee stock purchase plan) that vest over time. Standard employee benefits include paid/unpaid leaves, medical/dental/vision insurance, 401(k) plan, disability, life insurance, health savings/flexible spending accounts, and wellness programs.

Diversity & Development: Not explicitly detailed beyond general talent management and employee value proposition.

Environmental & Social Impact

Environmental Commitments: Janux Therapeutics, Inc. and its third-party contractors are subject to numerous environmental, health, and safety laws and regulations, including those governing laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation, and disposal of hazardous materials and wastes. The company contracts with third parties for waste disposal.

Supply Chain Sustainability: No specific supply chain sustainability initiatives or programs are disclosed in the filing.

Social Impact Initiatives: No specific social impact or community investment initiatives are disclosed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• United States: Subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA), governing research, development, testing, manufacturing, approval (BLA), labeling, promotion, and distribution of biological products. Expedited programs like Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval are available. Orphan Drug Designation provides market exclusivity. Post-approval requirements include cGMP, GCP, adverse event reporting, and potential Risk Evaluation and Mitigation Strategies (REMS).
• European Union: Subject to regulation by the European Medicines Agency (EMA) and European Commission. Clinical trials are governed by the Clinical Trials Regulation (EU) No 536/2014 (CTR), effective January 31, 2025. Marketing authorization is primarily through the centralized procedure. Conditional approval and accelerated assessment procedures are available. Orphan Medicinal Product Designation provides 10 years of market exclusivity. Post-authorization requirements include pharmacovigilance systems and Risk Management Plans (RMPs). The Health Technology Assessment (HTA) Regulation (effective January 12, 2025) aims to boost cooperation among EU Member States in assessing health technologies. The Pharma Package (political agreement December 11, 2025) proposes changes to market protection periods and the Bolar exemption.

Trade & Export Controls: The company is subject to U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. Geopolitical actions, tariffs, and trade barriers could adversely affect its business, particularly given its reliance on international suppliers.

Legal Proceedings: Janux Therapeutics, Inc. is not currently a party to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: Not applicable due to net losses and a full valuation allowance against deferred tax assets.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2025, the company had $138.9 million in U.S. federal NOL carryforwards (of which $138.4 million have an indefinite carryforward period, limited to 80% of future taxable income) and $182.9 million in state NOL carryforwards (beginning to expire in 2037).
• Research & Development (R&D) Credit Carryforwards: As of December 31, 2025, the company had $14.6 million in federal R&D credit carryforwards (beginning to expire in 2037) and $7.4 million in state R&D credit carryforwards (do not expire).
• Valuation Allowance: Maintains a full valuation allowance against its deferred tax assets ($90.0 million as of December 31, 2025) due to uncertainties regarding their realization.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), signed July 4, 2025, which includes expensing of domestic R&E expenditures, increased interest expense deduction limits, and 100% bonus depreciation, did not have a material impact on the company's current or future effective tax rate or cash taxes paid for the year ended December 31, 2025.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Maintains workers’ compensation insurance. Plans to expand product liability insurance coverage upon obtaining marketing approval for product candidates. Maintains cybersecurity insurance.
• Risk Transfer Mechanisms: Does not maintain insurance for environmental liability or toxic tort claims.
• Cybersecurity: Implements various information security processes and measures, including an incident response policy, vulnerability management, disaster recovery plan, encryption, network security controls, and employee training. Utilizes third-party service providers for cybersecurity assessments and support.